Search
Selected Filter
Displaying 11–20 of 213 research results
-
With a founding investment from Hatteras Venture Partners, Atsena has raised a total of $8.15 million for its launch.
-
Researchers Identify Regions in the Retina to Target Therapies for Certain RP Patients
University of Pennsylvania investigators studied retinas of patients and canines with retinitis pigmentosa caused by mild mutations in RHO
-
jCyte Reports Promising Results for Phase 2b Clinical Trial of its Cellular Therapy for RP
The emerging therapy is designed to work independent of the mutated gene causing vision loss
-
AGTC Planning Phase 2/3 Clinical Trial for XLRP Gene Therapy
The company is also expanding its Phase ½ trial for the emerging treatment
-
A Phase 3 trial for the treatment is planned
-
Biogen Entering into Licensing Agreement with Mass Eye and Ear to Develop PRPF31 Gene Therapy
The goal of the partnership is to advance a PRPF31 gene therapy into a clinical trial
-
Bionic Sight Doses First Patient in Clinical Trial for Optogenetic Therapy
Treatment combines gene therapy and a device that generates and delivers retinal code
-
Microperimetry, which measures retinal sensitivity in the macular region, shows promise as outcome measure
-
Genentech’s Port Delivery System for Wet AMD Meets Primary Endpoint in Phase 3 Clinical Trial
Tiny implant provides continual delivery of anti-VEGF treatment for six months
-
Nacuity’s Emerging Anti-Oxidative Therapy Moves into Clinical Trial
The oral treatment shows promise for slowing vision loss in people with RP and Usher syndrome, regardless of genetic profile
